Results 21 to 30 of about 8,546 (246)

Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study

Molecular Autism, 2020
Background Tuberous sclerosis complex (TSC) is an autosomal dominant disease that affects multiple organs including the brain. TSC is strongly associated with broad neurodevelopmental disorders, including autism spectrum disorder symptomatology ...
Dorinde M. van Andel, Jan J. Sprengers, Bob Oranje, Floortje E. Scheepers, Floor E. Jansen, Hilgo Bruining   +5 more
doaj   +2 more sources

The Anticancer Activity for the Bumetanide-Based Analogs via Targeting the Tumor-Associated Membrane-Bound Human Carbonic Anhydrase-IX Enzyme

Pharmaceuticals, 2020
The membrane-bound human carbonic anhydrase (hCA) IX is widely recognized as a marker of tumor hypoxia and a prognostic factor within several human cancers. Being undetected in most normal tissues, hCA-IX implies the pharmacotherapeutic advent of reduced
Azizah M. Malebari, Tarek S. Ibrahim, Ibrahim M. Salem, Ismail Salama, Ahdab N. Khayyat, Samia M. Mostafa, Osama I. El-Sabbagh, Khaled M. Darwish   +7 more
doaj   +2 more sources

Longitudinal Effects of Bumetanide on Neuro-Cognitive Functioning in Drug-Resistant Epilepsy

Frontiers in Neurology, 2019
Antiepileptic drugs (AEDs) have repeatedly shown inconsistent and almost contradictory effects on the neurocognitive system, from substantial impairments in processing speed to the noticeable improvement in working memory and executive functioning ...
Zeinab Gharaylou, Lida Shafaghi, Mohammad Ali Oghabian, Ali Yoonessi, Abbas Tafakhori, Esmaeil Shahsavand Ananloo, Mahmoudreza Hadjighassem, Mahmoudreza Hadjighassem   +7 more
doaj   +2 more sources

Bumetanide As a Candidate Treatment for Behavioral Problems in Tuberous Sclerosis Complex

Frontiers in Neurology, 2017
BackgroundRecent studies indicate excitatory GABA action in and around tubers in patients with tuberous sclerosis complex (TSC). This may contribute to recurrent seizures and behavioral problems that may be treated by agents that enhance GABAergic ...
Chantal Vlaskamp, Simon-Shlomo Poil, Floor Jansen, Klaus Linkenkaer-Hansen, Sarah Durston, Bob Oranje, Hilgo Bruining   +6 more
doaj   +2 more sources

Effect of Co-administration of Bumetanide and Phenobarbital on Seizure Attacks in Temporal Lobe Epilepsy

Basic and Clinical Neuroscience, 2018
Introduction: The resistance of temporal lobe epilepsy to classic drugs is thought to be due to disruption in the excitation/inhibition of this pathway.
Reza Rahmanzadeh, Soraya Mehrabi, Mahmood Barati, Milad Ahmadi, Fereshteh Golab, Sareh Kazmi, Mohammad Taghi Joghataei, Morteza Seifi, Mazaher Gholipourmalekabadi   +8 more
doaj   +1 more source

Bumetanide Therapeutic Effect in Children and Adolescents With Autism Spectrum Disorder: A Review Study

Basic and Clinical Neuroscience, 2019
Introduction: Autism Spectrum Disorder (ASD) is characterized by several impairments in communications and social interactions, as well as restricted interests or stereotyped behaviors.
Raheleh Mollajani, Mohamad Taghi Joghataei, Mehdi Tehrani-doost   +2 more
doaj   +2 more sources

Not All Leg Swelling Is Volume Overload: Point-of-Care Ultrasound and Sirolimus-Associated Lymphedema After Combined Heart-Kidney Transplant. [PDF]

Clin Case Rep
Multi‐organ point‐of‐care ultrasound in a combined heart‐kidney transplant recipient with refractory leg edema demonstrated bilateral A‐lines, a collapsible inferior vena cava, and preserved biventricular function, excluding cardiogenic congestion. Right heart catheterization confirmed a low‐filling‐pressure, high‐output state.
Boyle R, Patel N.
europepmc   +2 more sources

Bumetanide for neonatal seizures: No light in the pharmacokinetic/dynamic tunnel

Epilepsia, 2022
In his editorial, Kevin Staley criticizes our recent work demonstrating the lack of effect of bumetanide in a novel model of neonatal seizures. The main points in our response are that (1) our work is on an asphyxia model, not one on "hypercarbia only"; (
K. Kaila, W. Löscher
semanticscholar   +1 more source

Symptom improvement in children with autism spectrum disorder following bumetanide administration is associated with decreased GABA/glutamate ratios

Translational Psychiatry, 2020
Bumetanide has been reported to alter synaptic excitation–inhibition (E-I) balance by potentiating the action of γ-aminobutyric acid (GABA), thereby attenuating the severity of autism spectrum disorder (ASD) in animal models.
Lingli Zhang, Chu-Chung Huang, Yuan Dai, Q. Luo, Yiting Ji, Kai Wang, Shining Deng, Juehua Yu, Mingyu Xu, Xiujuan Du, Yun Tang, Chun Shen, Jianfeng Feng, B. Sahakian, Ching-Po Lin, Fei Li   +15 more
semanticscholar   +1 more source

Clarifications regarding bumetanide for neonatal seizures

Epilepsia, 2022
A recent Phase II randomized, controlled trial of bumetanide as an adjunctive treatment for neonatal seizures showed a robust efficacy signal and no evidence of toxicity.
K. Staley
semanticscholar   +1 more source